BladderLight™: transforming urine cytology for the diagnosis and management of bladder cancer

 Bladder cancer: the clinical background

Bladder cancer is a common cancer, with over 429,000 new cases diagnosed globally in 2012, and it is an expensive cancer, costing the UK alone over £50 million per year. Currently, the gold standard diagnosis and management tool for bladder cancer is cystoscopy, which is expensive, uncomfortable and carries a risk of infection. Because of the high recurrence rate of bladder cancer (up to 35% in the first 3 years), these shortcomings are exacerbated by the need for repeated surveillance, which may extend to quarterly cystoscopies for 1-2 years post-surgery, every 6 months in year 3-4, and annually thereafter.

The Cytosystems’ alternative: BladderLight™

Compared to cystoscopy, BladderLight™ is:

  • cost-effective
  • non-invasive
  • more comfortable for patients
  • free from risk of infection
  • highly accurate.

BladderLight™ employs the latest diagnostic technologies to create a full stratification package:

  • improved cell collection,
  • sensitive and specific molecular marker, reducing the level of false positives that would be present in a molecular-only approach
  • whole-cell approach
  • digitized analysis

 BladderLight™ is easily integrated into current clinical practice, and significantly enhances the capability of cytology to match the standards of accuracy of current cystoscopy.  

 Clinical benefits

  • User-friendly cell collection device that rapidly preserve the cells of interest
  • Clinically verified assay based on established universal MCM biomarker technology
  • Whole-cell approach for improved clinical decisions by reducing the level of false positives by not relying solely on a molecular approach.
  • Significantly cost-effective procedures
  • Highly accurate diagnosis, with high specificity and sensitivity
  • Readily integrates into current clinical practice
  • Non-invasive, eliminating risk of infection for patients
  • Suitable for surveillance and monitoring of disease
  • Automated analysis systems are more time-efficient for cytopathologists.